Skip to main content
S&P 5007,744.72+1.02%DOW53,712.20+1.23%NASDAQ26,573.92+1.36%BTC$80,670.00+4.76%ETH$2,488.47+4.28%GOLD$4,556.90+3.22%OIL$92.27+1.38%
Smart Investors Daily
ZV

NASDAQ · ZVSA

ZyVersa Therapeutics, Inc.

Healthcare · Biotechnology

$0.11

Up+$0.01 (+8.01%)

Updated Sep 3, 2026, 3:31 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.09M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.11 – $1.67
Volume
5.73K
Avg. volume
41.55K

Price performance

ZVSA price history

1M range · 0 trading sessions · Daily adjusted prices

ZVSA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ZVSA news

The latest Smart Investors Daily articles mentioning ZVSA.

Stock researchCompany · Overview

ZVSA research

Overview

Company profile and research snapshot.

Company profile

ZYVERSA THERAPEUTICS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ZVSA recent ratings
DateFirmRatingTarget
Mar 26, 2024HC Wainwright & Co.Buy—
Mar 12, 2024HC Wainwright & Co.Buy—
Feb 29, 2024HC Wainwright & Co.Buy—
Sep 8, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 19, 2025

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases.The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS) with potential indication expansion in Alport syndrome and diabetic kidney disease.The lead indication for IC 100 is cardiometabolic conditio

globenewswire.com · Nov 19, 2025

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, reports financial results for the quarter ended September 30, 2025.

GlobeNewswire Inc. · Aug 9, 2024

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, reported progress in its Phase 2a trial for Cholesterol Efflux Mediator™ VAR 200 in diabetic kidney disease and plans for its Inflammasome ASC Inhibitor IC 100 in obesity with metabolic complications. The company raised $0.8 million from warrant exercises and expects its current cash to fund operations on a month-to-month basis.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By